Andrew Combs Acquires 100,000 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) Stock

Prelude Therapeutics Incorporated (NASDAQ:PRLD) insider Andrew Combs acquired 100,000 shares of the business’s stock in a transaction dated Tuesday, March 25th. The shares were acquired at an average price of $0.69 per share, for a total transaction of $69,000.00. Following the acquisition, the insider now directly owns 480,123 shares in the company, valued at $331,284.87. This represents a 26.31 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.

Prelude Therapeutics Price Performance

Shares of Prelude Therapeutics stock opened at $0.80 on Friday. The firm has a market cap of $44.11 million, a price-to-earnings ratio of -0.45 and a beta of 1.43. Prelude Therapeutics Incorporated has a one year low of $0.63 and a one year high of $6.80. The stock’s 50-day moving average is $0.89 and its 200-day moving average is $1.32.

Prelude Therapeutics (NASDAQ:PRLD) last released its quarterly earnings results on Monday, March 10th. The company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.11. The firm had revenue of $4.00 million for the quarter. On average, equities analysts expect that Prelude Therapeutics Incorporated will post -1.81 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, JMP Securities reaffirmed a “market outperform” rating and issued a $4.00 price target (down previously from $7.00) on shares of Prelude Therapeutics in a research note on Wednesday, December 11th.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in PRLD. BNP Paribas Financial Markets acquired a new position in shares of Prelude Therapeutics during the 4th quarter worth about $26,000. Barclays PLC boosted its position in Prelude Therapeutics by 86.0% during the third quarter. Barclays PLC now owns 27,165 shares of the company’s stock valued at $57,000 after purchasing an additional 12,564 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Prelude Therapeutics by 925.0% during the fourth quarter. JPMorgan Chase & Co. now owns 61,149 shares of the company’s stock valued at $78,000 after purchasing an additional 55,183 shares during the last quarter. XTX Topco Ltd acquired a new position in shares of Prelude Therapeutics during the 3rd quarter worth approximately $100,000. Finally, Deutsche Bank AG raised its stake in shares of Prelude Therapeutics by 747.6% during the 4th quarter. Deutsche Bank AG now owns 123,899 shares of the company’s stock worth $159,000 after purchasing an additional 109,281 shares in the last quarter. Institutional investors own 79.72% of the company’s stock.

Prelude Therapeutics Company Profile

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.